Literature DB >> 21896402

[Somatostatin in breast cancer].

Albane Frati1, Martine Antoine, Anita Rodenas, Joseph Gligorov, Roman Rouzier, Elisabeth Chéreau.   

Abstract

In man, somatostatin is a hormone mostly produced by hypothalamus. It plays different parts in hormonal regulation through many specific receptors in human body. It has also two interesting actions such as an anti-secretory activity, mostly on the gastrointestinal system and an antiproliferative action on tumor cells. Many synthetic somatostatin analogues, more stable than the natural one, have been developed and are already used in digestive surgery to treat postoperative digestive fistula. Also, the development of specific polyclonal antibodies allowed the identification of five specific somatostatin receptors and their localization in different cell species. The presence of the five receptors in breast cancer cells has than been demonstrated. The purpose of this literature review is to clarify the potential antitumor effect of somatastatin analogues in breast cancer; its use as a preventive agent on lymphorrhea after breast surgery and its employment in imaging for early breast cancer detection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896402     DOI: 10.1684/abc.2011.0588

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  2 in total

1.  The use of lanreotide in the management of lymphorrhea after an aortic valve replacement.

Authors:  Jean Lemaitre; Bernard Segers; Eric Lebrun
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-06-29

2.  Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study.

Authors:  Elisabeth Chéreau; Catherine Uzan; Emmanuelle Boutmy-Deslandes; Sarah Zohar; Corinne Bézu; Chafika Mazouni; Jean-Rémi Garbay; Emile Daraï; Roman Rouzier
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.